Incidence of Nephrotoxicity and Association With Vancomycin Use in Intensive Care Unit Patients With Pneumonia: Retrospective Analysis of the IMPACT-HAP Database

Clinical Therapeutics

Volumn 34, Issue 1, 2012, Pages 149-157

  Cano, Ennie L ^a   Haque, Nadia Z ^b   Welch, Verna L ^c   Cely, Cynthia M ^a   Peyrani, Paula ^d   Scerpella, Ernesto G ^c   Ford, Kimbal D ^c   Zervos, Marcus J ^e   Ramirez, Julio A ^d   Kett, Daniel H ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

^c PFIZER INC   (United States)

^d University of Louisville School of Medicine   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Intensive care; Nephrotoxicity; Nosocomial pneumonia; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; CREATININE; VANCOMYCIN;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DATA BASE; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CREATININE; DATABASES AS TOPIC; FEMALE; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; VANCOMYCIN;

EID: 84856176691     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.12.013     Document Type: Article

References (29)

1. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society and the Infectious Diseases Society of America.
2. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
3. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:e18-e55.
4. Cantu T.G., Yamanaka-Yuen N.A., Lietman P.S. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994, 18:533-543.
5. Cunha B.A., Mohan S.S., Hamid N., et al. Cost-ineffectiveness of serum vancomycin levels. Eur J Clin Microbiol Infect Dis 2007, 26:509-511.
6. Sorrell T.C., Collignon P.J. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985, 16:235-241.
7. Wong-Beringer A., Joo J., Tse E., Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2010, 37:95-101.
8. Bosso J.A., Nappi J., Rudisill C., et al. The relationship between vancomycin trough concentrations and nephrotoxicty: a prospective multicenter trial. Antimicrob Agents Chemother 2011, 55:5475-5479.
9. Jeffres M.N., Isakow W., Doherty J.A., et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007, 29:1107-1115.
10. Hermsen E.D., Hanson M., Sankaranarayanan J., et al. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010, 9:9-14.
11. McKamy S., Hernandez E., Jahng M., et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011, 158:422-426.
12. Nguyen M, Wong J, Lee C, et al. Nephrotoxicity associated with high dose vs standard dose vancomycin therapy. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, Ill. Abstract K-1096.
13. Prabaker K, Tran T, Pratummas T, et al. Association of vancomycin trough levels with nephrotoxicity. Abstract presented at: 47th Annual Meeting of Infectious Diseases Societyof America (IDSA); October 29 to November 1, 2009; Philadelphia, Penn. Abstract 192.
14. Lodise T.P., Lomaestro B., Graves J., Drusano G.L. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336.
15. Mangino J.E., Peyrani P., Ford K.D., et al. Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study. Crit Care 2011, 15:R38.
16. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
17. Lodise T.P., Patel N., Lomaestro B.M., et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009, 49:507-514.
18. Field A., Miles J. Discovering Statistics Using SAS 2010, Sage Publications Ltd, Thousand Oaks, Calif.
19. Munro B.H. Statistical Methods for Health Care Research 2004, Lippincott Williams & Wilkins, Baltimore, Md.
20. Vieira J.M., Castro I., Curvello-Neto A., et al. Effect of acute kidney injury on weaning from mechanical ventilation in critically ill patients. Crit Care Med 2007, 35:184-191.
21. Macedo E., Castro I., Yu L., et al. Impact of mild acute kidney injury (AKI) on outcome after open repair of aortic aneurysms. Ren Fail 2008, 30:287-296.
22. Chertow G.M., Burdick E., Honour M., et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005, 16:3365-3370.
23. Hidayat L.K., Hsu D.I., Quist R., et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
24. Ingram P.R., Lye D.C., Tambyah P.A., et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008, 62:168-171.
25. Matsko SM, Johns ST, Moise PA. Impact of vancomycin (V) exposure and other clinical characteristics on nephrotoxicity. Abstract presented at: 48th Annual Meeting of the Infectious Diseases Society of America; October 21-24, 2010; Vancouver, British Columbia, Canada. Abstract 972.
26. Jeffres M.N., Isakow W., Doherty J.A., et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006, 130:947-955.
27. Kett D.H., Cano E., Quartin A.A., et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011, 11:181-189.
28. Venkataraman R., Kellum J.A. Defining acute renal failure: the RIFLE criteria. J Intensive Care Med 2007, 22:187-193.
29. Mehta R.L., Kellum J.A., Shah S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31.